Text Size

Glaucoma Research Foundation to Host Third Annual Glaucoma 360 New Horizons Forum

San Francisco, CA - January 16, 2014: Glaucoma Research Foundation will host the third annual Glaucoma 360 New Horizons Forum on February 7, 2014 at the historic Palace Hotel in San Francisco. The singular goal of this endeavor is to speed the development of new, more effective therapies and diagnostics for glaucoma patients.

Glaucoma 360 was founded by Adrienne Graves, PhD, and Andrew G. Iwach, MD, both of whom serve on the Glaucoma Research Foundation Board of Directors. Drs. Graves and Iwach also serve as Co-Chairs for Glaucoma 360. Dr. Graves said “We are showcasing early-stage companies who are developing new glaucoma drugs, devices, and drug delivery systems. By putting them together with venture capitalists, industry executives, FDA leaders, and clinicians, we hope to stimulate and facilitate key discussions and connections. It's a way for the Glaucoma Research Foundation to serve as a catalyst in the development of new glaucoma therapies."

Dr. Iwach, the Foundation’s Board Chair and Executive Director at the Glaucoma Center of San Francisco, added “It is a changing field, and we are delighted and honored that we are able to assemble such an accomplished group, all dedicated to new developments in glaucoma.”


Robert N. Weinreb, MD, Chairman and Director of the Shiley Eye Center at the University of California, San Diego, will give the inaugural Drs. Henry and Frederick Sutro Memorial Lecture, the Forum’s keynote address.

Attendees and speakers include nationally and internationally respected leaders in medicine, science, business, venture capital, and the FDA. The meeting’s format includes presentations by company CEO’s on the latest glaucoma developments, industry panel discussions, and key topics including reimbursement, funding opportunities, and building strategic partnerships in order to advance innovations.

Speakers and Panelists at New Horizons Forum


Speakers, panelists and discussion leaders include Stuart B. Abelson, MBA, President and CEO, Ora, Inc. (Andover, MA); Ike Ahmed, MD, FRCSC, Assistant Professor, Faculty of Medicine, University of Toronto (Toronto, ON, Canada); Alan S. Crandall, MD, Sr. Vice Chairman of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah (Salt Lake City, UT); Emmett Cunningham, Jr., MD, PhD, MPH, Partner, Clarus Ventures (San Francisco, CA); Eugene de Juan, Jr., MD, Founder and Vice-Chairman, ForSight Labs (Menlo Park, CA); Alfredo Dubra, PhD, Assistant Professor and Co-Director, Advanced Ocular Imaging Program (AOIP), Medical College of Wisconsin (Milwaukee, WI); Ronald L. Gross, MD, Chair and Director, West Virginia University Eye Institute (Morgantown, WV); H. Dunbar Hoskins, Jr., MD, former EVP American Academy of Ophthalmology and Co-founder, Glaucoma Research Foundation (San Francisco, CA); L. Jay Katz, MD, Director, Glaucoma Services, Wills Eye Institute (Philadelphia, PA); Gil Kliman, MD, Managing Director, InterWest Partners (Menlo Park, CA); Eliot Lazar, MD, President, elCON Enterprises, Inc.(Buffalo, NY); Richard Lindstrom, MD, Founder, Minnesota Eye Consultants, PA (Minneapolis, MN); William J. Link, PhD, Managing Director, Versant Ventures (Newport Beach, CA); K. Angela MacFarlane, JD, President and CEO, ForSight Labs (Menlo Park, CA); Jim Mazzo, Operating Partner, Versant Ventures (Newport Beach, CA); J. Casey McGlynn, JD, Partner, Wilson Sonsini Goodrich & Rosati (San Francisco, CA); Eydie Miller-Ellis, MD, Professor of Clinical Ophthalmology, Director, Glaucoma Services, Scheie Eye Institute (Philadelphia, PA); Gary D. Novack, PhD, President, Pharmalogic Development, Inc. (San Rafael, CA); Michael O’Rourke, President and CEO, GrayBug (Baltimore, MD); William L. Rich, III, MD, FACS, Medical Director of Health Policy, American Academy of Ophthalmology (San Francisco, CA); Calvin Roberts, MD, Senior Vice President and Chief Medical Officer, Bausch + Lomb (Rochester, NY); Joel Schuman, MD, FACS, Chairman, Department of Ophthalmology, University of Pittsburgh (Pittsburgh, PA); Kuldev Singh, MD, MPH, Professor of Ophthalmology, Stanford University Medical Center (Stanford, CA); Russ Trenary, President and CEO, InnFocus Inc. (Miami, FL); William Tucker, PhD, MBA Executive Director, Innovation Alliances and Services, University of California, Office of the President (Oakland, CA); Tracy Valorie, Vice President, Pharmaceutical Marketing, Bausch + Lomb (Rochester, NY); Steven Vold, MD, Founder & CEO, Vold Vision, PLLC (Fayetteville, AR); and Ruth Williams, MD, President, Wheaton Eye Clinic (Wheaton, IL)

Presenting Companies

Presenting companies featured include AßSee; AcuMEMS, Inc.; Aerie Pharmaceuticals, Inc.; Amakem Therapeutics; Amorphex Therapeutics LLC; AqueSys, Inc.; CheckedUp; ClearSide Biomedical, Inc.; Envisia Therapeutics; Glaukos Corporation; GrayBug; iCare USA; InnFocus, Inc.; Kala Pharmaceuticals; Keep Your Sight; Ocular Therapeutix, Inc.; Ono Pharmaceutical Co., LTD; pSivida; SKS Ocular LLC; Solx, Inc.; SwissMicro Technology; Transcend Medical; and Zordera.

Glaucoma 360

The New Horizons Forum is the centerpiece of Glaucoma 360, Glaucoma Research Foundation’s signature three-day event which includes a Gala honoring William J. Link, PhD, a leading venture capitalist and entrepreneur specializing in ophthalmology and singer-songwriter Judy Collins, as well as a continuing medical education program for clinicians. All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s research and education programs. To learn more about the February 6-8, 2014, event at San Francisco’s historic Palace Hotel, and to register, visit: www.glaucoma360.org.

About Glaucoma Research Foundation

Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America's oldest and most experienced nonprofit dedicated solely to its mission: to prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Glaucoma Research Foundation has invested more than $40 million into research and education to prevent vision loss from glaucoma.

Contact: Andrew Jackson, Director of Communications, phone (415) 986-3162

Last reviewed on October 29, 2017

Was this helpful? Yes No